Immunic to showcase phase 2 long-term MS disability data at MSToronto2026

Podcast: Proactive - Interviews for investors · Proactive

Opublikowano: 2026-10-21

Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Erik Lundgren joined Proactive's Stephen Gunnion to discuss four posters the company will present at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21–23. The presentations explore the potential of vidofludimus calcium, Immunic’s investigational oral therapy for multiple sclerosis (MS), across clinical, biomarker and preclinical research. One poster presents long-term disability data from the Phase 2 CALLIPER study in progressive MS. The analysis found that favourable trends in disability outcomes were maintained during the open-label extension phase, with low treatment discontinuation. The other posters examine how vidofludimus calcium may promote neuronal survival thro...